BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2019 9:49:23 AM | Browse: 796 | Download: 1396
 |
Received |
|
2019-01-02 02:09 |
|
Peer-Review Started |
|
2019-01-04 05:29 |
|
To Make the First Decision |
|
2019-01-27 05:32 |
|
Return for Revision |
|
2019-02-14 01:56 |
|
Revised |
|
2019-02-19 16:18 |
|
Second Decision |
|
2019-03-15 09:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-03-16 22:46 |
|
Articles in Press |
|
2019-03-16 22:46 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-03-28 01:18 |
|
Typeset the Manuscript |
|
2019-05-24 06:31 |
|
Publish the Manuscript Online |
|
2019-05-26 09:49 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in squamous cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Zhang, Hui-Min Chen, Yong-Mei Liu, Feng Peng, Min Yu, Wei-Ya Wang, Heng Xu, Yong-Sheng Wang and You Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81402561 |
|
| Corresponding Author |
Yan Zhang, PhD, Doctor, Professor, Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu 610041, Sichuan Province, China. zhang.yan@gmx.com |
| Key Words |
Squamous cell lung cancer; Lung cancer; Epidermal growth factor receptor mutation; T790M; Osimertinib; Tyrosine kinase inhibitor; Targeted therapy; Case report |
| Core Tip |
This is a case report of T790M-related acquired resistant squamous cell lung cancer (SCC) patient with good response to osimertinib, which indicated T790M is also an important mechanism for acquired resistance in SCC. In this case, the secondary T790M mutation of epidermal growth factor receptor (EGFR) was detected by next-generation sequencing (NGS) for frozen tissue but not detected by ARMS-PCR for formalin-fixed and paraffin-embedded sample, which suggests NGS and better preservation conditions may contribute to higher sensitivity of EGFR T790M detection. |
| Publish Date |
2019-05-26 09:49 |
| Citation |
Zhang Y, Chen HM, Liu YM, Peng F, Yu M, Wang WY, Xu H, Wang YS, Lu Y. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in squamous cell lung cancer: A case report. World J Clin Cases 2019; 7(10): 1221-1229 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i10/1221.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i10.1221 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
